

PROF. PIERRE-YVES DIETRICH

PUBLICATIONS

a. Articles originaux dans journaux avec politique éditoriale

1. Eliana Marinari, Valerie Dutoit, Sergey Nikolaev, Maria-Isabel Vargas, Karl Schaller, Johannes Alexander Lobrinus, Pierre-Yves Dietrich, Petros Tsantoulis, Denis Migliorini : Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread. *Neurol Genet* 2021; 7(2):e561. doi: 10.1212/NXG.0000000000000561
2. Marinari E, Allard M, Gustave R, Widmer V, Philippin G, Merkler D, Tsantoulis P, Dutoit V* and **Dietrich PY***. Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. *Oncoimmunology* 2020. In press. IF: 5.3
3. Ramzy GM, Koessler T, Ducrey E, McKee T, Ris F, Buchs N, Rubbia-Brandt L, **Dietrich PY**, Nowak-Sliwinska P. Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. *Cancers (Basel)*. 2020 May 31;12(6):1423. doi:10.3390/cancers12061423.PMID: 32486365
4. Gerber A, Da Silva Lopes A, Szüts N, Simon M, Ribordy-Baudat V, Ebnetter A, Perrinjaquet C, Gaignard ME, Nicodet D, Betticher D, Bula G, Cote M, Duchosal MA, Berret PA, **Dietrich PY**, Brennan C, Decosterd S, Ferreira Nobre S, Peters S, Koelliker R, Ninane F, Jeitziner MM, Colomer-Lahiguera S, Eicher M. Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool. *Health Sci Rep*. 2020 May 12;3(2):e160. doi: 10.1002/hsr2.160. eCollection 2020 Jun.PMID: 32405540
5. Relecom A, Federico M, Connors JM, Coiffier B, Biasoli I, Moccia A, Salles G, McKee T, Miralbell R, Borchmann P, Kuruvilla J, Johnson P, Cavalli F, Delavy M, **Dietrich PY**, Flahault A. Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. *Int J Environ Res Public Health*. 2020 Mar 9;17(5):1783. doi: 0.3390/ijerph17051783.PMID: 32182952 Review.
6. Dutoit V, Philippin G, Widmer V, Marinari E, Vuilleumier A, Migliorini D, Schaller K, **Dietrich PY**. Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients. *Front Oncol*. 2020 Feb 14;10:89. doi: 10.3389/fonc.2020.00089. eCollection 2020.PMID: 32117743
7. Meier RPH, Müller YD, **Dietrich PY**, Tille JC, Nikolaev S, Sartori A, Labidi-Galy I, Hernandez T, Kaur A, Hirsch HH, McKee TA, Toso C, Villard J, Berney T. Immunologic Clearance of a BK Virus-associated Metastatic Renal Allograft Carcinoma. *Transplantation*. 2020 Feb 21. doi: 10.1097/TP.0000000000003193. Online ahead of print.PMID: 32091486
8. Tsantoulis P, Delorenzi M, Bièche I, Vacher S, Mariani P, Cassoux N, Houy A, Stern MH, Roman-Roman S, **Dietrich PY**, Roth A, Cacheux W. Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma. *Sci Rep*. 2019 Nov 20;9(1):17178. doi: 10.1038/s41598-019-52841-y.PMID: 31748560

9. Migliorini D, Dutoit V D, Dutoit V, Allard M, Hallez NG, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, **Dietrich PY**. Phase I/II trial testing safety and immunogenicity of the multi-peptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. *Neuro Oncol*. 2019 Jul 11;21(7):923-933. doi: 10.1093/neuonc/noz040.
10. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep J, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanesian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee H, Singh-Jasuja H, Sahin U, **Dietrich PY**, Wick W: Actively personalized vaccination trial for newly diagnosed glioblastoma. *Nature*. 2019 Jan;565(7738):240-245. (IF 43.07)
11. Boydell E, Marinari E, Migliorini D, **Dietrich PY**, Patrikidou A, Dutoit V. Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients. *Cancers (Basel)*. 2019 Apr 2;11(4):464. doi: 10.3390/cancers11040464.
12. Tsantoulis P, Delorenzi M, Bièche I, Vacher S, Mariani P, Cassoux N, Houy A, Stern MH, Roman-Roman S, **Dietrich PY**, Roth A, Cacheux W. Prospective validation in epithelial tumors of a gene expression predictor in liver metastasis derived from uveal melanoma. *Sci Rep*. 2019 Nov 20;9(1):17178. doi: 10.1038/s41598-019-52841-y.
13. Elias KM, Tsantoulis P, Tille J-C, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Pappa G, Stuckelberger S, Hooda J, **Dietrich PY**, Goggins M, Kerr CL, Birrer M, Hirsch MS, Drapkin R, Labidi-Galy SI: Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. *J Pathol*. 2018 Dec;246(4):459-469. (IF 5.94)
14. Addeo A, Caparrotti F, Picardi C, **Dietrich P-Y**. Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point. *Journal of Clinical Oncology* 2018 Oct 22;JCO1800461. (IF 28.34)
15. Espeli V, Vergotte S, **Dietrich P-Y**, Pichard C, Siano M. Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy. *Nutr Cancer* 2018 Oct 1:1-6. (IF 2.02)
16. Genoud V, Marinari E, Nikolaev SI, Castle JC, Bukur V, **Dietrich PY**, Okada H, Walker PR: Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. *Oncoimmunology*. 2018 Sep 5;7(12):e1501137. (IF 5.33)
17. Bargetzi M, Baumann R, Cogliatti S, **Dietrich P-Y**, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T, Renner C: Diagnosis and treatment of follicular lymphoma: an update. *Swiss Medical Weekly* 2018 Jul 24;148:w14635.
18. Hottinger AF, Ben Aissa A, Espeli V, Squiban D, Dunkel N, Vargas MI, Hundsberger T, Mach N, Schaller K, Weber DC, Bodmer A, **Dietrich PY** : Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. *Br J Cancer*. 2018 Mar 20;118(6):e10. (IF 5.41)
19. Steiner R, Kridel R, Giostra E, McKee T, Achermann R, Mueller N, Manuel O, Dickenmann M, Schuurmans MM, de Leval L, Fehr T, Tinguely M, Binet I, Cogliatti S, Haralamvieva E, Koller M, The Swiss Transplant Cohort Study

- Stcs, **Dietrich PY**: Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. *Swiss Med Wkly*. 2018 Mar 8;148:w14596.
20. Migliorini D, **Dietrich PY**, Stupp R, Linette GP, Posey AD, June CH: CAR-T cell Therapies in Glioblastoma: a first look. *Clinical Cancer Research* 2018;24(3):535-540. (IF 8.91)
 21. Frigeri M, Meyer P, Banfi C, Giraud R, Hachulla AL, Spoerl D, Friedlaender A, Pugliesi-Rinaldi A, **Dietrich PY**: Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. *Can J Cardiol*. 2018 Jan;34(1):92.e1-92.e3. (IF 5.59)
 22. Cosset E, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, **Dietrich PY**, Weis SM, Mischel PS, Cheresch DA: Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. *Cancer Cell*. 2017 Dec 11;32(6):856-868. (IF 23.91)
 23. Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, **Dietrich PY**: Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. *OncoImmunology* 2017 Nov 7;7(2):e1391972. (IF 5.33)
 24. Cacheux W, Koessler T, Puppa G, Fernandez E, Ho L, **Dietrich PY**, Zilli T, Allal AS, Roche B, Ris F, Roth A: Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer. *Dig Liver Dis*. 2017 Nov;49(11):1262-1266. (IF 3.03)
 25. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; **ACT IV trial investigators**. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *Lancet Oncol*. 2017 Oct;18(10):1373-1385. (IF 35.38)
 26. Benkhoucha M, Molnarfi N, Kaya G, Belnoue E, Bjarnadóttir K, **Dietrich PY**, Walker PR, Martinvalet D, Derouazi M, Lalive PH: Identification of a novel population of highly cytotoxic c-Met-expressing CD8+ T lymphocytes. *EMBO Rep*. 2017 Sep;18(9):1545-1558. (IF 8.38)
 27. Pupo M, Bodmer A, Berto M, Maggiolini M, **Dietrich PY**, Picard D: A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells. *Oncotarget*. 2017 Jul 18;8(29):46728-46744. (IF 5.16)
 28. Migliorini D, Mach N, Aguiar D, Vernet R, Landis BN, Becker M, Mckee T, Dutoit V, **Dietrich PY**: First report of clinical responses to immunotherapy in three relapsing cases of chordoma after failure of standard therapies. *Oncoimmunology* 2017 Jun 21;6(8):e1338235. (IF 5.33)
 29. Visvikis-Siest S, Aldasoro Arguinano AA, Stathopoulou M, Xie T, Petrelis A, Weryha G, Froguel P, Meier-Abt P, Meyer UA, Mlakar V, Ansari M, Papassotiropoulos A, Dedoussis G, Pan B, Bühlmann RP, Noyer-Weidner M, **Dietrich PY**, Van Schaik R, Innocenti F, März W, Bekris LM, Deloukas P: 8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016. *Drug Metab Pers Ther*. 2017 May 24;32(2):119-127.
 30. Migliorini D, Aguiar D, Vargas MI, Lobrinus A, **Dietrich PY**: BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma. *Neurology*. 2017 Mar 28;88(13):1291-1293. (IF 8.68)

31. Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, Derouazu M, **Dietrich PY**, Walker PR, Martinvalet D: ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells. *EMBO J.* 2017 Mar 10. (IF 11.22)
32. Wanquet A, Birsén R, Bonnet C, Boubaya M, Choquet S, Dupuis J, Lepretre S, Re D, Fahri J, Michallet AS, Ysebaert L, Lemal R, Lamy T, Delarue R, Troussard X, Cymbalista F, Levy V, Dietrich PY, Leblond V, Aurran-Schleinitz T : Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients. *Br J Haematol.* 2017 Jan;176(1):37-49. (IF 5.2)
33. Migliorini D, Fertani S, Dietrich PY: Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing ? *CNS Oncol.* 2016 Oct;5(4):199-201.
34. Cosset E, Petty T, Dutoit V, Tirefort D, Otten-Hernandez P, Farinelli L, Dietrich PY, Preynat-Seauve O: Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness. *Biomaterials.* 2016 Nov;107:74-87. (IF10.27)
35. Riccadonna C, Yacoub Maroun C, Vuillefroy de Sully R, Boehler M, Calvo Tardón M, Jueliger S, Taverna P, Barba L, Marinari E, Pellegatta S, Bassoy EY, Martinvalet D, **Dietrich PY**, Walker PR: Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. *PLoS One.* 2016 Aug 31;11(8):e0162105. (IF 2.77)
36. Köessler T, Olivier T, Fertani S, Marinari E, Dutoit V, **Dietrich PY**: Ipilimumab-related hypophysitis may precede severe CNS immune attack. *Ann Oncol.* 2016 Oct;27(10):1975-6. (IF 13.92)
37. E Belnoue, WD Bernardino-Besson, H Gaertner, S Carboni, I Dunand-Sauthier, F Cerini, EM Suso-Inderberg, S Waelchli, S Koenig, AM Salazar, O Hartley, **PY Dietrich**, PR Walker, M Derouazi: Enhancing anti-tumor immune responses by optimized combinations of cell-penetrating peptide based-vaccines and adjuvants. *Mol Ther* 2016 Sep;24(9):1675-85. (IF 8.4)
38. V Espeli, E Ruegg, AF Hottinger, A Modaresi, **PY Dietrich**: Weekly multi-agent chemotherapy (CMF-b) for advanced non-melanoma skin cancer. *Anticancer Res* 2016; 36: 2359-64. (IF 1.93)
39. D Migliorini, S Haller, D Merkler, A Pugliesi, A Kika, K Schaller, B Leemann, **PY Dietrich**: Recurrent multiple CNS hemangioblastoma with VHL disease treated with pazopanib: a case report and literature review. *CNS Oncol* 2015; 4: 387-92.
40. R Vuillefroy de Sully, L Ducimetière, C Yacoub Maroun, **PY Dietrich**, M Derouazi, PR Walker. Phenotypic switch of CD8+ T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells. *Eur J Immunol* 2015, 45: 2263-75. (IF 4.69)
41. M Derouazi, W Di Bernardino-Besson, E Belnoue, S Hoepner, R Walther, M Benkhoucha, P Teta, Y Dufour, C Yacoub Maroun, A M Salazar, D Martinvalet, **PY Dietrich**, P R Walker. Novel cell-penetrating peptide-based vaccine induces robust CD4+ and CD8+ T cell-mediated antitumor immunity. *Cancer Res* 2015, 75: 3020-31. (IF 8.37)
42. C Luthy, A Pugliesi, E Rapiti, M Kossovsky, **PY Dietrich**, C Cedraschi, AF Allaz. Aggressiveness of cancer treatment in patients hospitalized in a supportive care unit. *Support Care Cancer* 2015; 23: 325-331. (IF 2.75)
43. F Favero, N McGranahan, M Salm, NJ Birkbak, JZ Sanborn, SC Benz, J Becq, JF Peden, Z Kingsbury, RJ Grocok, S Humphray, D Bentley, B Spencer-Dene, A Gutteridge, M Brada, S Roger, **PY Dietrich**, T Forsheew, M Gerlinger,, A Rowan, G Stamp, AC Eklund, Z Szallasi, C Swanton. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. *Ann Oncol* 2015; 26: 880-887. (IF 13.92)

44. S Nikolaev, F Santoni, M Garieri, P Makrythanasis, E Falconnet, M Guipponi, A Vannier, I Radovanovic, F Bena, F Forestier, K Schaller, V Dutoit, V Clement-Schatlo, **PY Dietrich**, SE Antonarakis. Extrachromosomal driver mutations in glioblastoma and low-grade glioma. *Nat Commun* 2014; 5: 5690. (IF 11.87)
45. **PY Dietrich**. Injecting hope into brain cancer treatment: is immunotherapy the way forward? *CNS Oncol* 2014; 3: 27-29.
46. M Pusztaszeri, **PY Dietrich**, C Duc, N Pasquier, T McKee, JC Pache. Fine-Needle Aspiration Biopsy for the Diagnosis of Metastatic Type B Thymoma to Lymph Nodes: A Case Report. *Diagn Cytopathol* 2014 Aug;42(8):683-52013. (IF 1.4)
47. AF Hottinger, AB Aissa, V Espeli, D Squiban, N Dunkel, MI Vargas, T Hundsberger, N Mach, K Schaller, DC Weber, A Bodmer, **PY Dietrich**. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. *Br J Cancer* 2014; 110: 2655-2661. (IF 5.41)
48. E Cosset, TJ Petty, V Dutoit, S Cordey, I Padioleau, P Otten-Hernandez, L Farinelli, L Kaiser, P Bruyère-Cerdan, D Tirefort, S Amar El-Dusouqui, Z Nayernia, KH Krause, EM Zdobnov, **PY Dietrich**, E Rigal, O Preynat-Seauve. Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response. *Int J Cancer* 2014; 135: 1381-1389. (IF 4.98)
49. Z Nayernia, L Turchi, E Cosset, H Peterson, V Dutoit, **PY Dietrich**, D Tirefort, H Chneiweiss, JA Lobrinus, KH Krause, T Virolle, O Preynat-Seauve. The relationship between brain tumor cell invasion of engineered neural tissues and in vivo features of glioblastoma. *Biomaterials* 2013; 34: 8279-8290. (IF 10.27)
50. S Hoepner, JM Loh, C Riccadonna, M Derouazi, CY Maroun, **PY Dietrich**, PR Walker. Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy. *PLoS One* 2013; 8: e63933. (IF 2.77)
51. AJ Templeton, V Dutoit, R Cathomas, C Rothermundt, D Bärtschi, C Dröge, O Gautschi, M Borner, E Fechter, F Stenner, R Winterhalder, B Müller, R Schiess, PJ Wild, JH Rüschoff, G Thalmann, **PY Dietrich**, R Aebbersold, D Klingbiel, S Gillissen, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naïve Patients with Castration-resistant Prostate Cancer (SAKK 08/08). *Eur Urol* 2013; 64: 150-158. (IF 17.29)
52. M Christoph Neidert, O Schoor, C Trautwein, N Trautwein, L Christ, A Melms, J Honegger, HG Rammensee, C Herold-Mende, **PY Dietrich**, S Stevanovic. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. *J Neurooncol* 2013; 111(3): 285-94 (IF: 3.2)
53. S Walter, T Weinschenk, A Stenzl, R Zdrojowy, A Pluzanska, C Szczylik, M Stahler, W Brugger, **PY Dietrich**, R Mendrzyk, N Hilf, O Schoor, J Fritsche, A Mahr, D Maurer, V Vass, C Trautwein, P Lewandrowski, C Flohr, H Pohla, JJ Stanczak, V Bronte, S Mandruzzato, T Biedermann, G Pawelec, E Derhovanessian, H Yamagishi, T Miki, F Hongo, N Takaha, K Hirakawa, H Tanaka, S Stevanovic, J Frisch, A Mayer-Mokler, A Kirner, HG Rammensee, C Reinhardt and H Singh-Jasuja. Multi-peptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nat Med* 2012; 18: 1254-1261. (IF: 22,46)
54. V Dutoit, C Herold-Mende, N Hilf, O Schoor, P Beckhove, J Bucher, K Dorsch, S Flohr, J Fritsche, P Lewandrowski, J Lohr, HG Rammensee, S Stevanovic, C Trautwein, V Vass, S Walter, PR Walker, T Weinschenk, H Singh-Jasuja, **PY Dietrich**. Exploiting the glioblastoma peptidome to discover novel tumor-associated antigens for immunotherapy. *Brain* 2012; 135: 1042-1054. (IF: 9,45)

55. AF Hottinger, AC George, M Bel, L Favet, C Combescure, S Meier, S Grillet, K Posfay-Barbe, L Kaiser, CA Siegrist⁺⁺, **PY Dietrich** : A prospective study of the factors shaping the antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. *The Oncologist* 2012; 17(3): 436-445. (IF: 3,9)
56. H Benhammane, G Mentha, E Tschanz, O El Mesbahi, **PY Dietrich**. Visceral Kaposi's Sarcoma Related to Human Herpesvirus-8 in Liver Transplant Recipient: Case Report and Literature Review. *Case Rep Oncol Med*; 2012:137291.
57. N Wickboldt, JC Pache, **PY Dietrich**, C Toso, C Gallay, L Brochard, P Merlani, D Pugin. Takotsubo syndrome secondary to adrenal adenocarcinoma cortisol as a possible culprit. *Am J Respir Crit Care Med* 2012; 186: 1061-1062. (IF: 11.08)
58. CA Siegrist, J Ambrosioni, M Bel, C Combescure, K Hadaya, PY Martin, PM Soccac, T Berney, S Noble, S Meier, K Posfay-Barbe, S Grillet, L Kaiser, C van Delden, H1N1 study group. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. *Antivir Ther* 2012; 17: 893-903. (IF:3.16)
59. CA Siegrist, C van Delden, M Bel, C. Combescure, C Delhumeau, M Cavassini, O Clerc, S Meier, K Hadaya, PM Soccac, S Yerly, L Kaiser, B Hirschel, A Calmy, H1N1 Study Group, Swiss HIV Cohort Study. Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine. *PLoS One* 2012; 7(7): e40428 (IF : 4.1)
60. P Bady, D Sciuscio, AC Diserens, J Bloch, MJ van den Bent, C Marosi, **PY Dietrich**, M Weller, L Mariani, FL Heppner, DR McDonald, D Lacombe, R Stupp, M Delorenzi ME Hegi. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. *Acta Neuropathol* 2012; 124(4): 547-60 (IF:9.320)
61. MG Schäppi, S Meier, M Bel, CA Siegrist, KM Posfay-Barbe, H1N1 Study Group. Protective antibody responses to influenza a/H1N1/09 vaccination in children with celiac disease. *J Pediatr Gastroenterol Nutr* 2012; 54(6): 817-819. (IF: 2,3)
62. C Renner, P Zinzani, R Gressin, D Klingbiel, **PY Dietrich**, F Hitz, M Bargetzi, W Mingrone, G Martinelli, A Trojan, K Bouabdallah, A Lohri, E Gyan, C Biaggi, S Cogliatti, F Bertoni, M Ghielmini, P Brauchli, N Ketterer. A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. *Haematologica* 2012; 97(7): 1088-1091. (IF: 6,4)
63. L Albiges, S Oudard, S Negrier, A Caty, G Gravis, F Joly, B Duclos, L Geoffrois, F Rolland, A Guillot, B Laguerre, E Legouffe, F Kohser, **PY Dietrich**, CA Theodore, B Escudier. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. *J Clin Oncol* 2012; 30(5): 482-487. (IF: 18,37)
64. A Calmy, M Bel, A Nguyen, C Combescure, C Delhumeau, S Meier, S Yerly, L Kaiser, B Hirschel, CA Siegrist, the H1N1 study group. Strong serological responses and HIV RNA increase following AS03-adjutant pandemic immunization in HIV-infected patients. *HIV Med* 2012; 13(4): 207-218. (IF: 3,0)
65. A Casini, E Tschanz, **PY Dietrich**, M Nendaz. Recurrent syncope due to esophageal squamous cell carcinoma. *Case Rep Oncol* 2011; 4: 433-438.
66. B Mohty, M Bel, M Vukicevic, M Nagy, E Levrat, S Meier, S Grillet, C Combescure, L Kaiser, Y Chalandon, J Passweg, CA Siegrist, E Roosnek, Blood and Marrow Transplant Program, Geneva University Hospitals H1N1 study group. Graft-versus-host disease in the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. *Haematologica* 2011, 96: 896-904. (IF: 6,4)

67. C Gabay, M Bel, C Combescure, C Ribi, S Meier, K Posfay-Barbe, S Grillet, JD Seebach, L Kaiser, W Wunderli, PA Guerne, CA Siegrist, H1N1 Study Group. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. *Arthritis Rheum* 2011; 63: 1486-1496. (IF: 7,86)
68. JC Tille, MF Pelte, J Schwartz, **PY Dietrich**, TA McKee: Plasmablastic lymphoma clinically presenting in the urinary tract. *Ann Diagn Pathol* 2012; 16(3): 219-223. (IF: 0,87)
69. AF Hottinger, L Favet, JC Pache, JB Martin, **PY Dietrich**: Delayed but complete response following oral Temozolomide treatment in melanoma leptomeningeal carcinomatosis. *Case Rep Oncol* 2011; 4: 211-215.
70. PR Benusiglio, TA McKee, X Montet, JM Dumonceau, L Favet, AC George, **PY Dietrich**: Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide : a case report. *J Med Case Reports* 2011; 5: 110.
71. *NN Tran Thang, M Derouazi, G Philippin, S Arcidiaco, W Di Berardino-Besson, F Masson, S Hoepner, K Burkhardt, A Guha, **PY Dietrich**, and PR Walker. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. *Cancer Res* 2010; 70(12): 4829-4839 (IF: 7.514)
72. G Martinelli, SF Hsu Schmitz, U Utiger, T Cerny, U Hess, S Bassi, E Okkinga, R Stupp, R Stahel, M Heizmann, D Vorobiof, A Lohri, **PY Dietrich**, E Zucca, M Ghilimini. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. *JCO* 2010; 28(29): 4480-4484. (IF: 18,37)
73. *M Tenan, M Aurrand-Lions, V Widmer, A Alimenti, K Burkhardt, F Lazeyras, MC Belkouch, P Hammel, D Aubry, PR Walker, M A Duchosal, B A Imhof, **PY Dietrich**: Cooperative expression of Junctional Adhesion Molecule-C and -B supports growth and invasion of glioma. *GLIA* 2010; 58(5) : 524-537. (IF : 5,559)
74. R Stupp, ME Hegi, B Neyns, R Goldbrunner, U Schlegel, PMJ Clement, GG Grabenbauer, AF Ochsenbein, M Simon, **PY Dietrich**, T Pietsch, C Hickings, JC Tonn, AC Diserens, A Pica, M Hermisson, S Kruger, M Picard, M Weller: Phase I/IIa study of Cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *JCO* 2010 ; 28(16) : 2712-2718 (IF: 17,15)
75. D Liénard, MF Avril, FA Le Gal, P Baumgaertner, W Vermeulen, A Bloom, C Geldhof, D Rimoldi, S Pagliusi, P Romero, **PY Dietrich**, N Corvaia, DE Speiser : Vaccination with Melan-A/Mart-1 peptide and klebsiella outer membrane protein P40 as an adjuvant. *J Immunotherapy* 2009 ; 32(8) : 875-873 (IF : 3,662)
76. *P Loubeyre, TA McKee, M Copercini, A Rosset, **PY Dietrich**. Diagnostic precision of image-guided multisampling core needle biopsy of suspected lymphomas in a primary care hospital. *Br J Cancer* 2009; 100: 1771-1776 (IF : 4,846)
77. V Clément, V Dutoit, D Marino, **PY Dietrich**, I Radovanovic. Limits of CD133 as a marker of glioma self-renewing cells. *Int J Cancer* 2009; 125: 244-248 (IF : 4,734)
78. I Inan, S de Sousa, PO Myers, B Bouclier, **PY Dietrich**, ME Hagen, P Morel. Management of malignant pleural effusion and ascites by a triple access multi perforated large diameter catheter port system. *World J Surg Oncol* 2008; 6: 85-87 (IF : 1)
79. *T Calzascia, JMS Loh, W Di Berardino-Besson, F masson, P Guillaume, PL Herrera, **PY Dietrich**, PR Walker: Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes. *GLIA* 2008; 56: 1625-1636 (IF : 5,559)

80. S Guiu, S Taillibert, O Chinot, L Taillandier, J Honorat, **PY Dietrich**, JP Maire, JS Guillamo, B Guiu, I Catry-Thomas, F Capelle, A Thiebaut, S Cartalat-Carel, C Deville, P Fumoleau, A Desjardins, K Hoang Xuan, B Chauffert : Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d'une étude multicentrique de l'Anocef. *Revue Neurologique* 2008 ; 164 : 588-594. (IF : 0,5)
81. A Murat, E Migliavacca, T Gorlia, WL Lambiv, T Shay, MF Hamou, N de Tribolet, L Regli, W Wick, MCM Kouwenhoven, JA Hainfellner, FL Heppner, **PY Dietrich**, Y Zimmer JG Cairncross, RC Janzer, E Domany, M Delorenzi, R Stupp, M E Hegi : Stem cell-related « Self-Renewal » signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. *JCO* 2008; 26(18): 3015-3024. (IF : 17,15)
82. *NN Tran Thang, G Abdo, JB Martin, Y Seium, H Yilmaz, MC Verbist, D Rufenacht, AP Sappino, **PY Dietrich**: Percutaneous cementoplasty in multiple myeloma: a valuable adjunct for pain control and ambulation maintenance. *Support Care Cancer* 2008, 16(8) : 891-896. (IF : 2,422)
83. **PY Dietrich**, M Duchosal: Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. *Ann Oncol.* 2008 Mar; 19(3): 595. (IF : 4,935)
84. S Sanchez-Politta, L Favet, K Kerl, **PY Dietrich**, V Piguet : Bortezomib-induced skin eruption. *Dermatology.* 2008; 216(2): 156-158. (IF : 1,886)
85. J Lübbe, I Masouyé, **PY Dietrich** : Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva). *Dermatology.* 2008; 216(3): 247-249. (IF : 1,886)
86. *F Masson, T Calzascia, W Di Bernardino-Besson, N de Tribolet, **PY Dietrich**, PR Walker: Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. *J Immunol* 2007; 179(2): 845-853. (IF : 6)
87. A Alimenti, J Delavelle, F Lazeyras, H Yilmaz, **PY Dietrich**, N de Tribolet, KO Lovblad: Monovoxel H magnetic resonance spectroscopy in the progression of gliomas. *Eur Neurol* 2007; 58(4): 198-209. (IF : 1,323)
88. *FA Le Gal, VM Widmer, V Dutoit, V Rubio-Godoy, J Schrenzel, PR Walker, P Romero, D Valmori, DE Speiser, **PY Dietrich** : Tissue homing and persistence of defined antigen-specific CD8+ tumor reactive T cell clones in long term melanoma survivors. *J Invest Dermatol* 2007; 127(3): 622-629. (IF : 5,251)
89. DE Speiser, P Baumgartner, C Barbey, V Rubio-Godoy, A Moulin, P Corthesy, E Devere, **PY Dietrich**, D Rimoldi, D Liénard, JC Cerottini, P Romero, N Rufer: A novel approach to characterize clonality and differentiation of human melanoma specific T cell responses: spontaneous priming and efficient boosting by vaccination. *J Immunol* 2006; 177(2): 1338-1348. (IF : 6)
90. I Uckay, J Garbino, **PY Dietrich**, B Ninet, P Rohner, V Jacomo: Recurrent bacteremia with *Helicobacter cinaedi*: case report and review of the literature. *BMC Infect Dis* 2006; 6: 86. (IF : 1,96)
91. A Cahana, Y Seium, M Diby, JB Martin, D Rufenacht, **PY Dietrich** : Percutaneous vertebroplasty in octogenarians: results and follow-up. *Pain Practice* 2005; 5(4): 316-323. (IF : 1,6)
92. B Jenny, J Harrison, D Baetens, JC Tille, K Burkhardt, H Mottaz, J Kiss, **PY Dietrich**, N de Tribolet, G Pizzolato, M Pepper: Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and hemangioblastomas. *J Pathol* 2006; 209(1): 34-43. (IF : 5,121)
93. MJ Pittet, A Gati, FA Le Gal, G Bioley, P Guillaume, M de Smedt, J Plum, DE Speiser, JC Cerottini, **PY Dietrich**, P Romero, A Zippelius : Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. *J Immunol* 2006; 176(4): 2230-2236. (IF : 6)

94. N van Baren, MC Bonnet, B Dreno, A Khammari, T Dorval, S Piperno-Neuman, D Liénard, D Speiser, M Marchand, VG Brichard, B Escudier, S Negrier, **PY Dietrich**, et al : Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells J Clin Oncol 2005; 23(35) 9008-9021. (IF : 17,15)
95. FA Le Gal, M Ayoub, V Dutoit, V Widmer, E Jager, JC Cerottini, **PY Dietrich**, D Valmori: Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother 2005; 28(3): 252-257. (IF : 3,644)
96. A Kelekis, KO Lovblad, A Mehdizade, T Somon, H Ylmaz, SG Wetzels, Y Seium, **PY Dietrich**, DA Ruefenacht, Pelvic osteoplasty in osteolytic metastases: technical approach under fluoroscopic guidance and early clinical results. JB Martin, J Vasc Interv Radiol 2005; 16(1):81-88. (IF : 2,675)
97. *R Wilmotte, K Burkhardt, V Kindler, MC Belkouch, G Dussex, N de Tribolet, PR Walker, **PY Dietrich**, B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 2005; 16(10): 1081-1085. (IF : 1,995)
98. *T Calzascia, F Masson, W Di Bernardino-Besson, E Contassot, R Wilmotte, M Aurrand-Lions, C Rüegg, **PY Dietrich**, PR Walker : Homing phenotypes of tumor-specific CD8 T cells are pre-determined at the tumor site by cross-presenting APCs. Immunity, 2005; 22: 175-184. (IF : 20,579)
99. P Loubeyre, M Copercini, **PY Dietrich** : Percutaneous CT-guided coaxial 18-gauge multisampling core needle biopsy of suspected thoracic lesions. Am J Roentgenol 2005; 185: 1294-1298. (IF :2,94)
100. N Meidenbauer, A Zippelius, MJ Pittet, M Laumer, S Vogl, J Heymann, M Rehli, B Seliger, S Schwarz, FA Le Gal, **PY Dietrich**, R Andreesen, P Romero, A Mackensen : High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma . Cancer Res 2004; 64: 6319-6326. (IF : 7, 514)
- 101.* E Contassot, R Wilmotte, M Tenan, MC Belkouch, V Schnuriger, N de Tribolet, K Burkhardt, **PY Dietrich** : Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol 2004; 63(9): 956-963. (IF : 5.140)
- 102.D Liénard, D Rimoldi, M Marchand, **PY Dietrich** , N Van Baren, C Geldhof, P Batard, P Guillaume, M Ayyoub , MJ Pittet, A Zippelius, K Fleischhauer, F Lejeune, JC Cerottini, P Romero, DE Speiser: Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunol 2004; 4:4-11. (IF 3.8)
103. M Hegi, AC Diserens, S Godard, **PY Dietrich**, L Regli, S Ostermann, P Otten, G van Melle, N de Tribolet, R Stupp: Clinical trial substantiates the predictive value of MGMT-methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10(6): 1871-1874. (IF 6,488)
104. A Zippelius, G Bioley, FA Le Gal, N Rufer, M Brandes, P Batard, M de Smedt, J Plum, JC Cerottini, **PY Dietrich**, P Romero, M Pittet : Human thymus exports naïve CD8 T cells that can home to non-lymphoid tissues. J Immunol 2004; 172(5): 2773-2777. (IF 6)
105. E Contassot, M Tenan, V Schnuriger, MF Pelte, **PY Dietrich** : Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor. Gynecol Oncol 2004; 93(1): 182-188. (IF 2.341)
106. S Godard, G Getz, M Delorenzi, P Farmer, H Kobayashi, I Desbaillets, M Nozaki, AC Diserens, MF Hamou, **PY Dietrich**, L Regli, RC Janzer, P Bucher, R Stupp, N de Tribolet, E Domany, M Hegi: Classification of human

- astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. *Cancer Res* 2003; 63: 6613-6625 (IF:8,649)
107. * T Calzascia, W Di Bernardino Besson, R Wilmotte, F Masson, N de Tribolet, **PY Dietrich**, and PR Walker : Cutting edge: Cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. *J. Immunol.* 2003; 171(5) 2187-2191. (IF: 6,702)
108. * **PY Dietrich**, FA Le Gal, V Dutoit, MJ Pittet, L Trautman, A Zippelius, I Cognet, V Widmer, PR Walker, et al : Prevalent role of T Cell Receptor (TCR)- α chain in the selection of the preimmune TCR repertoire specific for a human self-antigen. *J Immunol* 2003; 170(10): 5103-5109. (IF 6,702)
109. A Conconi, G Martinelli, C Thieblemont, AJ Ferreri, L Devizzi, F Peccarori, M Ponzoni, E Pedrinis, S Dell'Oro, C Pruneri, V Filipazzi, **PY Dietrich**, AM Gianni, B Coiffier, F Cavalli, E Zucca: Clinical activity of Rituximab in extragonadal marginal zone B-cell lymphoma of MALT type. *Blood* 2003; 102(8): 2741-2745. (IF 10,120)
110. A Kelekis, JB Martin, T Somon, SG Wetzel, **PY Dietrich**, DA Ruefenacht : Radicular pain after vertebroplasty: compression or irritation of the nerve root? Initial experience with the “cooling system”. *Spine* 2003; 28(14):265-269. (IF 2,676)
111. JB Martin, SG Wetzel, Y Seium, **PY Dietrich**, T Somon, P Gailloud, M Payer, A Kelekis, DA Ruefenacht : Percutaneous vertebroplasty in metastatic disease : Transpedicular access and treatment of lysed pedicles – initial experience. *Radiology* 2003; 229(2): 593-597. (IF 4,815)
112. * **PY Dietrich**, PR Walker, P Saas : Death receptors on reactive astrocytes : a key role in the fine tuning of brain inflammation. *Neurology* 2003; 60(4): 548-554. (IF 5.678)
113. M Katoh, R Wilmotte, MC Belkouch, N de Tribolet, GP Pizzolato, **PY Dietrich** : Survivin in brain tumors : an attractive target for immunotherapy. *J Neurooncol* 2003; 64(1-2) : 71-76. (IF : 1.568)
114. T Matthes, L Kaiser, D Weber, AM Kurt, **PY Dietrich** : CMV colitis : a severe complication after standard therapy. *Acta Oncologica* 2002; 41(7/8): 704-706. (IF 2,460)
115. V Dutoit, V Rubio-Godoy, MJ Pittet, A Zippelius, **PY Dietrich**, FA Le Gal, P Guillaume, P Romero, JC Cerottini, RA Houghten, C Pinilla, D Valmori: Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-A peptide multimer+ CD8+ T cells in humans. *J Exp Med* 2002; 196: 207-216. (IF 15.302)
116. * P Saas, Paul R Walker, AL Quiquerez, DE Chalmers, JF Arrighi, A Liénard, J Boucraut, **PY Dietrich**: A self-defense mechanism of astrocytes to Fas mediated death involving IL-8 and CXCR2. *NeuroReport* 2002; 13(15): 1921-1924. (IF 2.503)
117. * D Valmori, V Dutoit, V Schnuriger, AL Quiquerez, MJ Pittet, P Guillaume, V Rubio-Godoy, PR Walker, D Rimoldi, D Lienard, JC Cerottini, P Romero, **PY Dietrich** : Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. *J Immunol* 2002; 168(8) : 4231-4240. (IF:6,702)
118. D Valmori, C Scheibenbogen, V Dutoit, D Nagorsen, AM Asemisen, V Rubio-Godoy, D Rimoldi, P Guillaume, P Romero, D Schadendorf, M Lipp, **PY Dietrich**, E Thiel, JC Cerottini, D Lienard, U Keilholz : Circulating tumor-reactive CD8(+) T cells in melanoma patients contain CD45RA(+)/CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. *Cancer Res* 2002 ; 62(6) : 1743-1750. (IF:8,649)
119. R Stupp, **PY Dietrich**, S Ostermann Kraljevic, et al : Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. *J Clin Oncol*, 2002 ; 20(5) : 1375-1382. (IF:10,864)

120. C Rochlitz, B Dreno, P Jantscheff, F Cavalli, P Squiban, MF Avril, R Morant, R Herrmann, **PY Dietrich**, R Dummer : Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2 : Phase II randomised study comparing two dose levels. *Cancer Gene Ther* 2002; 9(3): 289-295. (IF:3,688)
121. G Perrin, D Speiser, A Porret, AL Quiquerez, PR Walker, **PY Dietrich** : Sister cytotoxic CD8+ T cell clones differing in natural killer inhibitory receptor expression in human astrocytoma. *Immunol Lett.* 2002 ; 81(2) : 125-132. (IF:1,710)
122. JB Martin, Ph Gailloud, **PY Dietrich**, et al : Direct transoral approach to C2 for percutaneous vertebroplasty. A technical note. *Cardiovascular Interv Rad* 2002; 25(6): 517-519 (IF:1207)
123. A Zouhair, D Weber, Y Belkacémi, N Ketterer N, **PY Dietrich**, S Villa, L Scandolaro, S Bieri, G Studer, F Delacretaz, Ch Girardet, RO Mirimanoff, M Ozsahin : Outcome and patterns of failure in testicular lymphoma : a multicenter rare cancer network study. *Int J Radiat Oncol Biol Phys* 2002 ; 52(3) : 652-656. (IF:4,285)
124. C Lhommé, Ph Brault, JH Bourhis, P Pautier, N Dohollou, **PY Dietrich**, G Akbar-Zadeh, C Lucas, JP Pico, M Hayat : Prevention of menstruation with leuprorelin (GnRH Agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies : a pilot study. *Leuk Lymphoma* 2001 ; 42(5) : 1033-1041. (IF:1,163)
125. A Benjelloun, J Delavelle, F Lazeyras, **PY Dietrich** : High efficacy of Temozolomide in a patient with Gliomatosis Cerebri. *Neurology* 2001; 57 : 1932-1933. (IF:5,678)
126. V Dutoit, V Rubio Godoy, **PY Dietrich**, Donato Rimoldi, D Liénard, Ph Guillaume, et al : Heterogeneous T cell response to MAGE-A10₂₅₄₋₂₆₂ : High avidity specific cytolytic T lymphocytes show superior antitumor activity. *Cancer Res* 2001; 61 : 5850-5856. (IF:8,649)
127. M Brada, K Hoang-Xuan, R Rampling, **PY Dietrich**, LY Dirix, D Macdonald, et al : Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. *Ann Oncol* 2001 ; 12 : 259-266. (IF:3,605)
128. L Castagna, E Benhamou, E Pedraza, M Luboinski, M Forni, I Brandes, JL Pico, **PY Dietrich**: Prevention of mucositis in bone marrow transplantation : a double blind randomised controlled trial of sucralfate. *Ann Oncol* 2001; 12: 953-955. (IF:3,605)
129. * **PY Dietrich**, PR Walker, AL Quiquerez, G Perrin, V Dutoit, D Liénard, P Guillaume, JC Cerottini, P Romero, D Valmori: Melanoma patients respond to a CTL-defined self peptide with diverse and non overlapping TCR repertoires. *Cancer Res* 2001 ; 61 : 2047-2054. (IF:8,649)
130. PR Walker, T Calzascia, V Schnuriger, D Chalmers, P Saas, **PY Dietrich**: Loss of Fas (CD95/APO-1) expression by antigen specific cytotoxic T cells is reversed by inhibiting DNA methylation. *Cell Immunol* 2000 ; 206 : 51-58. (IF:1,829)
131. P Jeannin, G Magistrelli, JP Aubry, JF Gauchat, T Renno, G Caron, N Herbault, L Goetsch, **PY Dietrich**, A Blaecke, JY Bonnefoy, Y Delneste: Soluble CD86 is a costimulatory molecule for human T cells. *Immunity* 2000 ; 13 : 303-312. (IF:16,016)
132. * P Saas, J Boucraut, PR Walker, AL Quiquerez, M Billot, S Desplat-Jego, Y Chicheportiche, **PY Dietrich**: TWEAK stimulation of astrocytes and the pro-inflammatory consequences. *Glia* 2000 ; 32 : 102-107. (IF:4,677)
133. D Valmori, V Dutoit, D Liénard, F Lejeune, D Speiser, D Rimoldi, V Cerundolo, **PY Dietrich**, JC Cerottini, P Romero: Tetramer-Guided Analysis of TCR β -Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients. *J Immunol* 2000 ; 165 : 533-538. (IF:6,702)

- 134.* PR Walker, T Calzascia, V Schnuriger, N Scamuffa, P Saas, N de Tribolet, **PY Dietrich**: The brain parenchyma is permissive for full anti-tumor CTL effector function, even in the absence of CD4 T cells. *J Immunol* 2000 ; 165 : 3128-3135. (IF:6,702)
- 135.FM Laurencet, S Anchisi, E Tullen, **PY Dietrich**: Mental Neuropathy : report of 5 cases and review of the literature. *Crit Rev Oncol Hematol* 2000 ; 34 : 71-79. (IF:2,979)
- 136.* G Perrin, V Schnuriger, AL Quiquerez, P Saas, C Pannetier, JM Tiercy, JP Aubry, **PY Dietrich***, PR Walker* : Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. *Int Immunol* 1999; 11 (8) : 1337-1349. Both last authors share senior authorship. (IF:3,690)
137. C Rochlitz, P Jantscheff, G Bongartz, **PY Dietrich**, et al : Gene therapy study of cytokine-transfected xenogeneic cells (Vero-IL2) in patients with metastatic solid tumors. *Cancer Gene Therap* 1999; 6(3) : 271-281. (IF:3,688)
138. M Marchand, N van Baren, P Weynants, V Brichard, B Dreno, MH Tessier, E Rankin, G Parmiani, F Arienti, Y Humblet, A Bourlond, R Vanwijck, D Liénard, M Beaudin, **PY Dietrich**, et al : Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 1999 ; 80 : 219-230. (IF:4,375)
- 139.* P Saas, J Boucraut, AL Quiquerez, V Schnuriger, G Perrin, S Desplat-Jego, D Bernard, PR Walker, **PY Dietrich** : CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses : a key role in brain inflammation ? *J Immunol* 1999; 162 : 2326-2333. (IF:6,702)
140. G Zona, N de Tribolet, G Pizzolato, **PY Dietrich**: Etoposide-Carboplatin association as « emergency » up-front chemotherapy in a case of life-threatening adult medulloblastoma. *J Neurooncol* 1998; 39 : 253-259. (IF:1,568)
141. B Escudier, A Ravaud, D Berton, C Chevreau, JY Douillard, **PY Dietrich**: Phase II study of interferon- α and all-trans retinoic acid in metastatic renal cell carcinoma. *J Immunother* 1998; 21(1) : 62-64. (IF:3,983)
142. N Rosenblatt-Velin, JF Arrighi, **PY Dietrich**, V Schnuriger, I Massouyé, C Hauser: Migration of transformed and nontransformed human T lymphocytes to skin in a chimeric human skin/SCID mouse model. *J Invest Dermatol* 1997; 109(96) : 744-750. (IF:4,194)
143. GA Waanders, D Rimoldi, D Liénard, S Carrel, F Lejeune F, **PY Dietrich**, JC Cerottini, P Romero: Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. *Clin Cancer Res* 1997; 3: 685-696. (IF:6,511)
144. **PY Dietrich**, PR Walker, V Schnuriger, P Saas, M Guillard, C Gaudin, A Caignard: T cell receptor analysis reveals significant repertoire selection during in vitro lymphocyte culture. *Int Immunol* 1997; 9(8): 1073-1083. (IF:4,375)
145. CY Manz, **PY Dietrich**, V Schnuriger, C Nissen, A Wodnar-Filipowics: Analysis of T-cell receptor beta chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. *Blood Cell Mol Dis* 1997; 23: 110-122. (IF:1,991)
- 146.* PR Walker, P Saas, **PY Dietrich**: The role of Fas Ligand (CD95L) in immune escape: the tumor cell strikes back. *J Immunol* 1997; 158; 4521-4524. (IF:6,702)
- 147.* P Saas, PR Walker, M Hahne, AL Quiquerez, V Schnuriger, G Perrin, L French, E Van Meir, N de Tribolet, J Tschopp, **PY Dietrich**: Fas ligand expression by astrocytoma *in vivo*: maintaining immune privilege in the brain? *J Clin Invest* 1997; 99: 1173-1178. (IF:14,307)
148. FM Laurencet, GB Zulian, **PY Dietrich**, S Anchisi, B Mermillod, P Alberto: Traitement des lymphomes non hodgkiniens agressifs: expérience d'un hôpital général. *Bull Cancer* 1996; 83: 864-869. (IF:0,654)

149. B Bonnotte, AM Burdiles, J Chehimi, G Carayol, C Pardoux, **PY Dietrich**, M Kubin, JY Blay, A Caignard, A Ibrahim, E Robinet, M Hayat, JL Pico, JH Bourhis, S Chouaib: Serum interleukin-12 levels in patients undergoing allogeneic or autologous bone marrow transplantation. *Eur Cytokine Netw* 1996; 7: 389-394. (IF:1,679)
150. A Caignard, M Guillard, C Gaudin, B Escudier, F Triebel, **PY Dietrich**: In situ demonstration of renal cell carcinoma specific T cell clones. *Int J Cancer* 1996; 66: 564-570. (IF:4,375)
151. O Rutschmann, HG Khan, **PY Dietrich**: Huge seminal vesicle distension mimicking urinary retention. *J Urol* 1996; 156: 183-184. (IF:3,297)
152. E Angevin, D Valteau-Couanet, F Farace, **PY Dietrich**, A Lechesne, F Triebel, B Escudier: Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 in patients with advanced cancer. *J Immunoth* 1995; 18(3): 188-195. (IF:3,984)
153. F Farace, E Angevin, **PY Dietrich**, C Leboullaire, J Vanderplancke, B Escudier, F Triebel: Low dose IL-2 treatment: activation of discrete T and NK cell subpopulations in vivo. *Int J Cancer* 1995; 62: 523-528. (IF:4,375)
154. J Even, A Lim, I Puisieux, L Ferradini, **PY Dietrich**, C Pannetier, F Triebel, T Hercend, P Kourilsky: T cell repertoires in healthy and diseased human tissues analysed by T-cell receptor β -chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases. *Res Immunol* 1995; 146: 65-80. (IF:1,723)
155. G Zulian, **PY Dietrich**, S Anchisi, JC Pache, B Conne, C Rouden, P Alberto: Lymphoma of uncertain phenotype. *Ann Oncol* 1995; 6: 827-832. (IF:3,605)
156. B Escudier, F Farace, C Théodore, E Angevin, B Court, D Couanet, **PY Dietrich**, S Culine, M Pallardy, T Hercend, JP Droz: Traitement du cancer du rein métastatique avec un nouveau schéma d'interleukine-2: expérience de l'Institut Gustave Roussy. *Bull Cancer* 1995; 82: 296-302. (IF:0,654)
157. C Gaudin, **PY Dietrich**, S Robache, M Guillard, B Escudier, MJ Terrier-Lacombe, A Kumar, F Triebel, A Caignard: In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. *Cancer Res* 1995; 55: 685-690. (IF:8,649)
158. F Farace, F Kremer, **PY Dietrich**, C Gaudin, E Angevin, C Bayle, MH Courtier, Ch Bayle, T Hercend, F Triebel: Etude du répertoire des lymphocytes T chez des patients atteints de LLC stade A: mise en évidence d'expansions monoclonales de cellules T in vivo. *Bull Cancer* 1994; 81: 897-899. (IF:0,654)
159. F Farace, F Ordanlucci, **PY Dietrich**, C Gaudin, E Angevin, C Bayle, MH Courtier, Ch Bayle, T Hercend, F Triebel: T cell repertoire in patients with B-chronic lymphocytic leukemia: evidence for multiple in vivo T-cell clonal expansions. *J Immunol* 1994; 153: 4281-4290. (IF:6,702)
160. **PY Dietrich**, A Caignard, A Lim, V Chung, JL Pico, C Pannetier, P Kourilsky, T Hercend, J Even, F Triebel: In vivo T-cell clonal amplification at time of acute graft versus host disease. *Blood* 1994; 84: 2815-2820. (IF:10,120)
161. **PY Dietrich**, M Henry-Amar, JM Cosset, J Bosq, S Bodis, M Hayat: Second primary cancers after Hodgkin's disease: a protective role for the spleen? *Blood* 1994; 84: 1209-1215. (IF:10,120)
162. A Caignard, **PY Dietrich**, V Morand, A Lim, C Pannetier, AM Leridant, T Hercend, J Even, P Kourilsky, F Triebel: Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck. *Cancer Res* 1994; 54: 1292-1297. (IF:8,649)
163. S Bodis, J Benard, J Bosq, P Ardouin, S Prost, A Venuat, **PY Dietrich**, L Ramirez, P Mauch, JL Pico, M Hayat: MDR-1 gene expression in a multidrug resistant human non-Hodgkin lymphoma (NHL) xenograft model. *Int J Oncol* 1993; 3: 109-114. (IF: 2,536)

164. E Angevin, F Farace, C Genevee, M Henry-Amar, A Caignard, **PY Dietrich**, B Escudier, T Hercend, F Triebel: Analysis of T-cell receptor variable gene segment usage in peripheral blood lymphocytes of advanced cancer patients. *Int J Cancer* 1993; 54: 60-67. (IF: 4,375)
165. F Farace, E Angevin, B Escudier, A Caignard, **PY Dietrich**, C Genevee, T Hercend, F Triebel: Influence of Interleukin-2 administration on the expression of T cell receptor V gene segments in patients with renal cell carcinoma. *Int J Cancer* 1993; 54: 741-747. (IF:4,375)
166. S Bodis, M Henry-Amar, J Bosq, JMV Burgers, WAM Mellink, **PY Dietrich**, N Dupouy, EM Noordijk, JMM Raemaekers, J Thomas, H Eghbali, R Régnier, A Tanguy, L Verdonck, J Michel, R Zittoun, H Kerkhofs, M Hayat: Late relapse in early stage Hodgkin's disease patients enrolled on EORTC protocols. *J Clin Oncol* 1993; 11: 225-232. (IF:10,864)
167. **PY Dietrich**, A Rieder, M Apro, G P Pizzolato: Primary diffuse leptomeningeal gliomatosis: a neoplastic cause of chronic meningitis. *J Neurol Oncol* 1993; 15: 275-283. (IF:1,568)
168. **PY Dietrich**, A Caignard, A Diu, C Genevee, JL Pico, M Henry-Amar, J Bosq, E Angevin, F Triebel, T Hercend: Analysis of T cell receptor variability in transplanted patients with human cutaneous acute graft versus host disease. *Blood* 1992; 80: 2419-2424. (IF:10,120)
169. C Genevee, A Diu, J Nierat, A Caignard, **PY Dietrich**, L Ferradini, S Roman-Roman, F Triebel, T Hercend: An experimentally validated panel of subfamily-specific oligonucleotide primers (V α -w29/V β -w24) for the study of human T-cell receptor V gene segments usage by polymerase chain reaction. *Eur J Immunol* 1992; 22: 1261-1269. (IF:4,536)
170. JM Cosset, M Henry-Amar, **PY Dietrich**, G Socie, T Girinski, M Hayat, M Tubiana: Les tumeurs solides secondaires après irradiation pour maladie de Hodgkin; l'expérience de l'Institut Gustave-Roussy. *Bull Cancer* 1992; 79: 387-388. (IF:0,654)
171. **PY Dietrich**, E Pedraza, Ch Bayle, JL Pico, M Hayat: La leucémie prolymphocytaire. *Bull Cancer* 1991; 78: 801-806. (IF:0,654)
172. **PY Dietrich**, E Pedraza, O Casiraghi, C Bayle, M Hayat, JL Pico: Cardiac arrest due to leukostasis in prolymphocytic leukemia. *Br J Haematol* 1991; 78: 122-123. (IF:3,489)
173. I Garcia, **PY Dietrich**, G Vauthier, M Apro, P Vadas, E Engel: Alterations of c-erb-B2, C-myc and C-Ha-ras proto-oncogenes in breast carcinomas and clinical correlations. *Cancer Res* 1989; 49: 6675-6679. (IF:8,649)
174. AP Sappino, **PY Dietrich**, O Skalli, G Gabbiani: Colonic pericryptal fibroblasts: differentiation pattern and expression in epithelial proliferative lesions. *Virchows Archiv A Pathol Anat* 1989; 415: 551-557. (IF:2,357)
175. **PY Dietrich**, J Bille, C Fontalliet, C Regamey: Histoplasmose disséminée à *Histoplasma capsulatum* chez un patient présentant un syndrome d'immunodéficience acquise (SIDA). *Schweiz Med Wschr* 1987; 117: 1289-1296. (IF:0,258)
176. P Petropoulos, **PY Dietrich**, J Ammann, G Ayer, P Buchmann, S Martinoli: Prophylaxie antibiotique par dose unique pour la chirurgie colorectale élektive. *Helv Chir Acta* 1985; 52: 703-706. (IF:0,047)
177. P Creissard, **PY Dietrich**, M Tadie, P Freger, J Godlewski, F Mangez, A Thierry, JL Sautreaux, MC Pelikan, R Kotbane: Une série de 106 cas d'anévrismes rompus opérés dans la première semaine. *Neurochir* 1984; 30: 283-288. (IF:0,390)

b. Articles de revues dans journaux à politique éditoriale

1. Timothée Olivier, Eugenio Fernandez, Intidhar Labidi-Galy, **PY Dietrich**, Veronica Rodriguez-Bravo, Giulia Baciarello, Karim Fizazi, Anna Patrikidou: Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? *Cancer Treat Rev* 2021, in pres
2. **Dietrich PY**, Dutoit V. Therapeutic vaccination for glioblastoma. *Med Sci (Paris)*. 2020 Apr;36(4):319-322. doi: 10.1051/medsci/2020047. Epub 2020 May 1. PMID: 32356704
3. Dutoit V, Migliorini D, **Dietrich PY**: Current strategies for vaccination in glioblastoma. *Curr Opin Oncol* 2019; 31(6): 514-21(IF 3.26)
4. Michielin O, P Tsantoulis, K Homicsko, Y Christinat, L de Leval, B Bisig, E Missiaglia, V Zoete, F Krebs, A Fortin, L Perey, V Kirchner, S Nikolaev, P Chappuis, L Rubbia, T Mckee, G Coukos, **PY Dietrich**. The Romand Network of Oncology: bridging the gap of personalised oncology. *Swiss Med Weekly* 2019 in press
5. Cavo Tardón M, Allard M, Dutoit V, **Dietrich PY**, Walker PR. Peptides as cancer vaccines. *Curr Opin Pharmacol*. 2019 Mar 1;47:20-26. (IF 5.2)
6. Dutoit V, Migliorini D, **Dietrich PY**, Walker PR : Immunotherapy of Malignant Tumors in the Brain : How Different from Other Sites ? *Front Oncol*. 2016 Dec 7;6:256. (IF 4.13)
7. Vuillefroy de Silly R, **Dietrich PY**, Walker PR. Hypoxia and antitumor CD8+-T cells: An incompatible alliance? *Oncoimmunology*. 2016 Sep 9 ;5(12). (IF 5.33)
8. Walker PR, Belnoue E, **Dietrich PY**, Derouazi M. Cell-penetrating peptides-the Swiss Army knife of cancer vaccines. *Oncoimmunology*. 2015 Dec 10;5(3):e1095435. (IF 5.33)
9. V Dutoit, D Migliorini, PR Walker, **PY Dietrich**. Immunotherapy of brain tumors. *Prog Tumor Res* 2015: 42:11-21. (IF 7.72)
10. D Migliorini, **PY Dietrich**, PR Walker. Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies. *Immunotherapy* 2013 ; 11 : 1147-1150. (IF 3.02)
11. F Buchegger, SM Larson, JP Mach, Y Chalandon, **PY Dietrich**, A Cairoli, JO Prior, P Romero, DE Speiser. Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. *Clin Dev Immunol* 2013; 2013:875343. (IF 3.6)
12. R Kridel, **PY Dietrich**. Prevention of central nervous system relapse in diffuse large B-cell lymphoma: evidence and controversies. *Lancet Oncology* 2011; 12(13): 1258-1266. (IF: 22,59) (IF)
13. **PY Dietrich**, V Dutoit, Nam N Tran Thang, Paul R Walker. T cell Immunotherapy for malignant glioma : towards a combined approach. *Curr Opin Oncol* 2010; 22: 604-610. (IF: 4,1)
14. A Bodmer, L Goetsch, L favet, C baily, N Corvaia, **PY Dietrich**. The potential of monoclonal antibodies in cancer: established trastuzumab and cetuximab and promising targets IGF-R1 and c-MET. *Med Sci* 2009; 25(12): 1090-98. (IF: 0.331)
15. E Roosnek, M Burjanadze, **PY Dietrich**, T Matthes, J Passweg, B Huard. Tumors that look for their springtime in APRIL. *Crit Rev Oncol Hematol* 2009; 72(2): 91-97. (IF : 4,589)
16. R Stupp, AF Hottinger, MJ van den Bent, **PY Dietrich**, AA Brandes. Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. *Ann Oncol* 2008; 19 suppl 7: 209-216 (IF : 4,935)

17. * PR Walker, T Calzascia, N de Tribolet, PY **Dietrich**. T cell immune responses in the brain and their relevance for cerebral malignancies. *Brain Research Reviews*, 2003; 42: 97-122. (IF: 6,504)
18. P Romero, D Valmori, MJ Pittet, A Zippelius, D Rimoldi, F Levy, V Dutoit, V Rubio-Godoy, O Michielin, P Guillaume, P Batard, IF Luescher, F Lejeune, D Liénard, N Rufer, **PY Dietrich**, DE Speiser, JC Cerottini. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. *Immunol Rev* 2002; 188 : 81-96. (IF 7.052)
19. PR Walker, T Calzascia, **PY Dietrich**. All in the head : Obstacles for immune rejection of brain tumors. *Immunology* 2002; 107 : 28-38. (IF:2.853)
20. PR Walker, **PY Dietrich**. Immune escape of gliomas. *Prog Brain Res* 2001 ; 132 : 685-698. (IF:2,072)
21. **PY Dietrich**. La réponse immunitaire anti-tumorale : Les gliomes sont-ils concernés ? *Revue Neurologique* 2001; 157: 1339-1348. (IF:0,456)
22. **PY Dietrich**, PR Walker. Echappement et tolérance des tumeurs à l'apoptose. *Méd/Sci* 2000 ; 16 : 491-499. (IF:0,331)
23. R Hermann, **PY Dietrich**. Chemotherapie maligner gliome. *Onkologie* 1998 ; 4 : 618-621. (IF:1,154)
24. PR Walker, P Saas, **PY Dietrich**. Tumor expression of Fas ligand (CD95L) and the consequences. *Curr opin Immunol* 1998; 10 : 564- 572. (IF:12,118)
25. B Escudier, **PY Dietrich**. Retinoids in the management of renal cell carcinoma. *Retinoids* 1998 ; 14(2) : 51-53. (IF:0)
26. P Hoesli, AP Sappino, N de Tribolet, **PY Dietrich**. Malignant glioma: should chemotherapy be overthrown by experimental treatments? *Ann Oncol* 1998; 9 : 589-600. (IF:3,605)
27. **PY Dietrich**, P Saas, PR Walker, N de Tribolet. Immunobiology of gliomas: new perspectives for therapy. *Ann N Y Acad Sci* 1997 ; 824 : 124-140. (IF: 1,892)
28. J Hildebrand, O Dewitte, **PY Dietrich**, N de Tribolet. Management of malignant brain tumors. *Eur Neurol* 1997; 38: 238-253. (IF:1,042)
29. **PY Dietrich**, F Farace, A Caignard, B Escudier, F Triebel. L'immunothérapie anti-cancéreuse : bases immunologiques, réalité et espoirs. *Bull Cancer* 1993; 80: 584-600. (IF:1,09)
30. M Henry-Amar and **PY Dietrich**. Acute leukemia after the treatment for Hodgkin's disease. *Hematol Oncol Clin North Amer* 1993; 7: 369-387. (IF:2,108)
31. **PY Dietrich**, JP Droz: Cancer à cellules rénales: oncogènes et gènes suppresseurs de tumeur. *La Revue du Praticien* 1992; 42: 1236-1240. (IF:0)

c. Lettres publiées dans des journaux à politique éditoriale

1. Addeo A, Banna GL, **Dietrich PY**. Learning from the past to design better trials in second-line treatment for mesothelioma patients. *Ecancermedalscience*. 2018;12:881. Published 2018 Nov 12.
2. R Stupp, S Ostermann-Kraljevic, **PY Dietrich**, RO Mirimanoff. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. *J Clin Oncol* 2002; 20: 3181. (IF 10,864)
3. **PY Dietrich**: intrathecal MTX for DLBCL: from inappropriate prophylactic tradition to a medical error ? *Blood* 2009; 114(9): 1999 (IF 10.3)
4. Y Chalandon, F Negro, D Hebert, **PY Dietrich** : Watchful policy for hepatitis B reactivation after intensive chemotherapy. *Ann Oncol* 1999; 10 : 483. (IF:3,605)
5. FM Laurencet, GB Zulian, **PY Dietrich**: Pneumothorax following induction chemotherapy for a germ cell tumor. *Eur J Cancer* 1997 ; 33: 169-170. (IF:3,694)
6. O Rutschmann, J-F Bolle, **PY Dietrich**: « Vivre ou laisser mourir ». *J Am Geriatr Soc* 1996; 44: 104. (IF:3,136)
7. S Anchisi, G Zulian, **PY Dietrich**, P Alberto: Cladribine and tumor lysis syndrome. *Eur J Cancer* 1994; 31A: 131-132. (IF:3,694)
8. **PY Dietrich**, S Bellefqih, M Henry-Amar, JM Cosset, M Hayat: Linitis plastica after Hodgkin's disease. *Lancet* 1993; 342: 57-58. (IF:18,316)
9. J Arroyo, B Ody, **PY Dietrich**, Ph Beris: Macroscopic hematuria in a hemoglobin S heterozygote with a concomitant chromosome with triple alfa loci: a possible pathophysiologic mechanism. *Eur J Hematol* 1989; 42: 312. (IF:1,665)
10. **PY Dietrich**, P Pugin, C Regamey, J Bille: Disseminated histoplasmosis and AIDS in Switzerland. *Lancet* 1986; ii: 752. (IF:18,316)

d. Articles dans journaux sans politique éditoriale

1. **Dietrich PY**, Aapro M, Peters S. Une période de craintes et de défis : vers un monde meilleur ? Rev Med Suisse. 2020 May 27;16(695):1071-1072.PMID: 32462833.
2. Zimmermann S, **Dietrich PY**, Michielin O, Betticher D, Peters S. Oncology: navigating the COVID-19 Pandemic and Steer the Course. Rev Med Suisse. 2020 Apr 29;16(N° 691-2):819-822.PMID: 32348043.
3. Peters S, **Dietrich PY**. Journée du cancer : mobiliser autour de la prévention. Rev Med Suisse. 2020 Feb 19;16(682):382-383.PMID: 32073779.
4. Aapro M, Peters S, **Dietrich PY**. De sérieuses préoccupations qui ne cachent pas nos espoirs. Rev Med Suisse. 2019 May 15;15(651):999-1000.
5. Peters S, **Dietrich PY**, Aapro M. De vrais espoirs et de sérieuses préoccupations. Rev Med Suisse. 2018 May 16;14(607):1011-1012.
6. Frigeri M, Brnic-Bontognali M, Galetti V, **Dietrich PY**, Bodmer A: “Doctor, I am fasting during chemotherapy”: illusion or new clinical facts? Rev Med Suisse. 2018 May 16;14(607):1034-1036.
7. Amram ML, **Dietrich PY**, Rochon F, Bolmont M, Bianchi-Demicheli F. Cancer and sexual medicine: a hand to the human. Rev Med Suisse. 2018 Mar 14;14(598):582-584.
8. Bolmont M, Amram ML, Rochon F, **Dietrich PY**, Bianchi-Demicheli F. The care of the sexuality among oncologic patients - A research project within the University hospitals of Geneva. Rev Med Suisse. 2018 Mar 14;14(598):578-581.
9. Bianchi-Demicheli F, **Dietrich PY**. Onco-sexologie : un regard au cœur des patients. Rev Med Suisse. 2018 Mar 14;14(598):555-556.
10. Aapro M, **Dietrich PY**, Peters S. L'accès à l'innovation. Rev Med Suisse. 2017 May 17;13(563):1027.
11. Migliorini D, Dutoit V, Walker PR, **Dietrich PY**. Brain tumor immunotherapy : illusion or hope ? Bull Cancer. 2017 May; 104(5):476-484. Doi: 10.1016/j.bulcan.2017.01.014. Epub 2017 Mar 17.
12. **Dietrich PY**, Coukos G, Aapro M. Traitement des cancers: n'oublions pas les enjeux humains et sociaux des progrès actuels et à venir ! Rev Med Suisse. 2016 May 18;12(519) :963-4.
13. **Dietrich PY**. Cancer research: opening frontiers and minds. Bulletin Suisse du Cancer 2016; 2: 103-104.
14. **Dietrich PY**. Cancer Centre Geneva University Hospital (HUG) – The patient at the heart of a comprehensive management. Bulletin Suisse du Cancer 2016; 1: 39-48.
15. Migliorini D, **Dietrich PY**. Immunotherapy for brain tumors : obstacles and perspectives ? Rev Med Suisse. 2016 Apr 27 ;12(516) :828-31.
16. I Nemitz, D Migliorini, **PY Dietrich**. Cerebral lymphoma: a classic presentation ? Rev Med Suisse 2015; 11: 371-373.
17. GJ Wirth, T Zilli, A Roth, ML Amram, C Biton, JC Tille, M Pusztaszeri, L Rubbia-Grandt, JP Vallée, T de Perrot, JP Willi, O Ratib, A BattaginFritsch, **PY Dietrich**, R Miralbell, C Iselin. Rev Med Suisse 2014; 10: 2302-2305.
18. C Py, **PY Dietrich**, A Ben Aissa. Vademecum of skeletal complications of malignancy. Rev Med Suisse 2013: 9: 1110-1113.
19. A Sarivalasis, ML Amram, **PY Dietrich**. Examples of tumor markers and their clinical utility. Rev Med Suisse 2013; 9: 1102-1107.

20. I Chofflon, **PY Dietrich**, NN Tran Thang. Antibody-drug conjugates: a new therapeutic class ? Rev Med Suisse 2013; 9: 1080-1082.
21. M Aapro, **PY Dietrich**, S Leyvraz. In Process Citation. Rev Med Suisse 2013; 9: 1067-1068.
22. PH Lalive, T Kuntzer, **PY Dietrich**. Neuropathies associated with paraproteinemia (monoclonal gammopathy). Rev Med Suisse 2013; 9: 929-933.
23. **PY Dietrich**. Diversité et personnalisation des traitements en oncologie. Rev Med Suisse 2011 ; 7 : 1123-1124.
24. C Joly, Jacqueline Ravel, A Pugliesi, L Bigler-Perrotin, M Chiki, **PY Dietrich**, P Dulguerov, R Miralbell, M Picard-Kossofsky, Y Seium, M Thériault, C Pichard. Integration of nutritional care into cancer treatment : need for improvement. Rev Med Suisse 2011; 7(137): 2252-6.
25. A Ben Aissa, AC George, FZ El M'Rabet, N Mach, **PY Dietrich**, A Pechère-Bertschi. Anticancer drugs under pressure. Rev Med Suisse 2011; 7: 1761-1766.
26. L Gétaz, N Mezger, V Piguet, **PY Dietrich**, L Favet. Lymphoma and pruritis: search for parasites. Rev Med Suisse 2009; 5: 1112-1114.
27. K Zaman, L Favet, C Schusterbauer, **PY Dietrich**. Bisphosphonates in oncology : update 2007. Rev Med Suisse 2007; 3(112): 1317-1318.
28. A Bodmer, MF Pelte, MC Verbist, **PY Dietrich**. New treatments for renal cell carcinoma: hope and limits. Rev Med Suisse 2007; 3(112): 1288, 1290-1292.
29. M Nobahar, K Burkhardt, J Delavelle, **PY Dietrich**. Les tumeurs cérébrales sont fréquentes : il faut y penser. Méd et Hyg 2004 ; 62 : 1489-1495.
30. JB Martin, **PY Dietrich**, A Hugli, AP Sappino, F Terrier, DA Ruefenacht. Vertébroplastie : indications, technique et résultats selon l'expérience genevoise. Méd et Hyg 2003 ; 61 : 570-578.
31. D Guggisberg, JP Cerottini, J Krischer, R Braun, **PY Dietrich**, D Lienard. Recommandations pour la prise en charge du mélanome. Rev Med Suisse Romande 2002 ; 122(1) : 5-8.
32. D Hebert, D Salomon, **PY Dietrich**. Chimiothérapie ambulatoire des carcinomes spinocellulaires de la peau. Méd et Hyg 2001; 56: 1166-1169.
33. D Valmori, P Romero, V Dutoit, M Pittet, **PY Dietrich**, D Speiser, P Guillaume, D Rimoldi, D Liénard, F Lejeune, JC Cerottini. HLA-class-I/peptide fluorescent tetramers for the analysis of tumor antigen specific T cell responses. Bulletin Suisse du Cancer 2001; 21: 6-12.
34. **PY Dietrich**. Active specific immunotherapy of metastatic melanoma with an anti-idiotypic vaccine : a phase I/II trial of I-Mel-2 plus SAF-M (comment). Biotherapy in Cancer 1998 ; 2(1) : 26-27.
35. P Hoesli, **PY Dietrich**. De la chimiothérapie aux thérapies biologiques expérimentales dans le traitement des gliomes malins. Méd et Hyg 1998, 56 : 1166-1169.
36. A Hugli, **PY Dietrich**. La méningite carcinomateuse. Méd et Hyg 1997 ; 55: 1330-1336.
37. **PY Dietrich**, PR Walker, EG Van Meir. Thérapie génique du cancer: une explosion de nouvelles stratégies thérapeutiques. Méd et Hyg 1997; 55: 1527-1535.
38. V Schnuriger, **PY Dietrich**. L'immunothérapie contre le cancer: et pourquoi pas ? Méd et Hyg 1995; 53: 1350-1357.
39. **PY Dietrich**. Le lymphocyte T, charnière de la réponse immunitaire antitumorale. Bulletin Suisse du Cancer 1994; 4: 128-132.

40. B Escudier, **PY Dietrich**. Le poumon et les traitements par Interleukine 2 et Interféron. Méd et Hyg 1992; 50: 1064-1065.
41. **PY Dietrich**, JM Cosset, M Henry-Amar. Cancers secondaires après maladie de Hodgkin. Méd et Hyg 1992; 50: 3358-3361.
42. **PY Dietrich**. La place de l'interféron alpha dans la stratégie thérapeutique en hématologie maligne. Méd et Hyg 1991; 49: 3022-3026.
43. I Brandes, **PY Dietrich**, E Pedraza, JL Pico. Alimentation orale au cours des greffes de moelle osseuse. Revue de l'association des diététiciens de langue française 1990; 3: 3-7.
44. **PY Dietrich**, B Chapuis. Traitement des lymphomes malins non hodgkiniens ganglionnaires de faible degré de malignité. Méd et Hyg 1989; 47: 3346-3352.
45. **PY Dietrich**, B Chapuis. Lymphomes malins à haut risque: attitude thérapeutique. Méd et Hyg 1989; 47: 3339-3345.
46. **PY Dietrich**, B Chapuis, C Helg. Facteurs de croissance hématopoïétiques. Méd et Hyg 1989; 47: 3353-3357.

e. Chapitres de livres

1. BG Roche, **PY Dietrich**, P Petropoulos: Naftidrofuryl versus placebo for the treatment of Fontaine stage II lower limb arteriopathy. In: « What is new in Angiology? Trends and Controversies », by P C MAURER et coll, Editions W Zuckschwerdt Verlag München, Bern, Wien, 1986, 553-554.
2. JL Pico, JP Droz, E Zambon, M Montastruc, A Gouyette, **PY Dietrich**, M Hayat: High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors. In: Neoadjuvant Chemotherapy: Third International Congress 1991. Editions Springer-Verlag, Paris, 311-313.
3. **PY Dietrich**, N de Tribolet: Immune response against malignant astrocytic tumors and related therapy. In « The molecular basis of neurosurgical disease », Editeurs C Raffel and GR Harsh IV. Editions Williams and Wilkins 1996: Concepts in Neurosurgery, chapter 13, 211-237.
4. **PY Dietrich**, A Hugli: Carcinomatous meningitis. ESMO Educational Book 1996, 183-190.
5. **PY Dietrich**: Traitements biologiques : cytokines, immunothérapie. Dans « Cancers : guide pratique d'évaluation, de traitement et de surveillance », Editeurs JM Andrieu, P Colonna, R Levy. Editions ESTEM, Paris, 1997, 190-208.
6. **PY Dietrich**: Immunothérapie des gliomes malins: vers une stratégie vaccinale? ESO (European School of Oncology) d'expression française, Nice, mars 1997. Educational Book, 173-187.
7. **PY Dietrich**, P Saas, PR Walker: Gene therapy based on the immune response against tumors: a new perspective for the treatment of malignant glioma. In The Biotherapy of cancers: from immunotherapy to gene therapy, Editeur S Chouaib. Edition INSERM, Paris, 1998, 375-401.
8. **PY Dietrich**, PR Walker, P Saas, N de Tribolet: Central nervous system tumors and the immune system. In « Clinical Neuroimmunology » Editors: J Antel, G Birbaum, HP Hartung. Editions Blackwell Science Inc., Malden, USA, 1998, chapter 15: 228-253.
9. C Rochlitz, P Jantscheff, G Bongartz, **PY Dietrich**, et al : Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors. Adv Exp Med Biol 1998, 451 : 531-537.
10. **PY Dietrich**, PR Walker, T Calzascia, N de Tribolet : Immunology of brain tumors and implications for immunotherapy. In Brain tumors : An encyclopedic approach. AH Kaye and ER Laws Jr (Eds.), Churchill Livingstone, Edinburgh, 2001, 135-150.
11. J Duff, **PY Dietrich**, N de Tribolet : Current therapies for malignant gliomas. In Brain Tumor Immunotherapy. Editor : D Bigner. Humana Press Inc, 2000, 73-90.
12. **PY Dietrich**, N de Tribolet. Nouvelles stratégies thérapeutiques des gliomes malins. Dans « Traité de Neurologie : volume neuro-oncologie. Editeurs : J Bogousslavsky, JM Leger, JL Mas. Editions DOIN, 2001, 203-221.
13. **PY Dietrich**, PR Walker and N de Tribolet. Aspects of Immunology applicable to brain tumour pathogenesis and treatment. In Youmans Neurological Surgery. 5th Edition, Winn, H. R. (Ed.), W. B. Saunders Company, Philadelphia, 2004: p135-150.
14. PR Walker, T Calzascia, N de Tribolet, and **PY Dietrich**. Central nervous system neoplastic diseases and the immune system. In Clinical Neuroimmunology. 2nd Edition, Antel, J., G. Birnbaum, H.-P. Hartung, and A. Vincent (Eds.), Oxford University Press, Oxford, 2005
15. PR Walker, RM Prins, **PY Dietrich**, LM Liau. Harnessing T-cell immunity to target brain tumors. In CNS Cancer, Models, Prognostic Factors and Targets and Therapeutic Approaches. E. G. Van Meir (Editor). New York: Humana Press. 2009; p1165-218.

f. Thèse & Livre

Doctorat en médecine:

Prophylaxie aux antibiotiques dans la chirurgie colorectale électorale: comparaison entre dose unique de ceftriaxone et doses multiples de cefotaxime et d'ornidazole, avec lavage orthograde mécanique rapide.

Thèse n°6092, janvier 1986, Genève, Suisse.

Thèse d'habilitation au titre de Privat-Docteur:

Tumour immunology: The case of malignant glioma.

Genève, 1996

Livres

PY Dietrich, E Gordon, A Pugliesi-Rinaldi

« J'ai envie de comprendre le cancer », Editeur: Planète Santé (2016)

Olivier Dessibourg, **Pierre-Yves Dietrich**, Jacques Fellay & Patrice Lalive

« Médicaments ciblés et tests associés, clés de la médecine de précision : percées des recherches cliniques, entre promesses et réalité : entretien avec Pierre-Yves Dietrich, Jacques Fellay & Patrice Lalive », Editeur : Planète Santé (2018)

g. Auteur d'abstracts et présentations à des conférences internationales

Valérie Dutoit, Denis Migliorini, Mathilde Allard, Eliana Marinari, Anna Patrikidou, Paul R Walker, Herold-Mende C, T Weinschenk, H Sing and **Pierre-Yves Dietrich**. « Vaccination using immunopeptidome-identified antigens for malignant glioma », PIVAC-18 meeting, Oslo, Norvège, 3-5 oct 2018.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep J, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee H, Singh-Jasuja H, Sahin U, **Dietrich PY**, Wick W. « The GAPVAC approach of actively personalized peptide vaccination for patients with newly diagnosed glioblastoma », SITC 33rd Annual Meeting, Washington, DC, November 2018.

Wolfgang Wick, **Pierre-Yves Dietrich**, Sabrina Kuttruff-Coqui, Norbert Hilf, Katrin Frenzel, Arie Admon, Sjoerd H. van der Burg, Andreas von Deimling, Cecile Gouttefangeas, Judith R. Kroep, Francisco Martinez-Ricarte, Hideho Okada, Christian H. Ottensmeier, Berta Ponsati, Hans S. Poulsen, Stefan Stevanović, Ghazaleh Tabatabai, Hans-Georg Rammensee, Ugur Sahin, Harpreet Singh-Jasuja. « GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma », Neurooncology session at 2018 ASCO Annual Meeting, June 2018.

Alfredo Addeo, Javier Torralvo, **Pierre-Yves Dietrich**. « Different degree of response to checkpoint inhibitors in metastatic NSCLC patients according to mutations within KRAS gene. », 2018 ASCO Annual Meeting, June 2018.

Bukur V., Frenzel K., Hilf N., Loewer M., Kuttruff-Coqui S., Deeg K., Diekmann J., Paruzynski A., Kreiter S., Admon A., van der Burg S., Dorner S., Fritsche J., Wagner C., Ulges A., Mendryzk R., Song C., Gouttefangeas C., R. Kroep J., Heesch S., Ludwig J., Dutoit V., Okada H., Ottensmeier C., Pawlowski N., Piro J., Platten M., Ponsati B., Poulsen H.S., Sahuquillo J., Martinez-Ricarte F., Schoor O., Stevanovic S., Straten P.T., Tabatabai G., Skardelly M., Weinschenk T., Rammensee H.-G., **Dietrich P.-Y.**, Singh-Jasuja H., Wick W. and Sahin U. « Glioma Actively Personalized Vaccine Consortium: Successful Clinical Translation of Mutated Peptide Vaccination», CIMT 2018 Annual Meeting.

C. Py, G. Gutknecht, V. Dutoit, A. Addeo, **P.-Y. Dietrich** « Prospective Immuno-biobank in NSCLC», IASLC 19th world conference on lung cancer (WCLC), Toronto, Canada, September 2018.

A. Addeo, A. Friedlander, C. Py, **P.-Y. Dietrich** « Detecting ALK rearrangements in NSCLC patients: IHC, FISH or NGS fusion? », IASLC 19th world conference on lung cancer (WCLC), Toronto, Canada, September 2018.